Us Bancorp \De\ Alnylam Pharmaceuticals, Inc. Transaction History

Us Bancorp \De\

$82.9 Billion
Q3 2025

A detailed history of Us Bancorp \De\ transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Us Bancorp \De\ holds 5,646 shares of ALNY stock, worth $2.54 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,646

Previous 4,700 20.13%

Holding current value

$2.54 Million

Previous $1.53 Million 68.02%

% of portfolio

0.0%

Previous 0.0%

33 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 10, 2025	BUY	$311.12 - $482.13 $294,319 - $456,094	946 Added 20.13%	5,646 $2.57 Million
Q2 2025 Jul 23, 2025	BUY	$224.32 - $326.09 $24,675 - $35,869	110 Added 2.4%	4,700 $1.53 Million
Q1 2025 May 08, 2025	SELL	$233.07 - $290.7 $44,749 - $55,814	-192 Reduced 4.02%	4,590 $1.24 Million
Q4 2024 Feb 05, 2025	SELL	$232.27 - $300.43 $184,886 - $239,142	-796 Reduced 14.27%	4,782 $1.13 Million
Q3 2024 Oct 28, 2024	SELL	$233.81 - $287.01 $354,455 - $435,107	-1,516 Reduced 21.37%	5,578 $1.53 Million

Q2 2024 Aug 06, 2024	BUY	$143.31 - $247.0 $76,527 - $131,898	534 Added 8.14%	7,094 $1.72 Million
Q1 2024 May 07, 2024	SELL	$146.51 - $198.2 $101,238 - $136,956	-691 Reduced 9.53%	6,560 $980,000
Q4 2023 Feb 09, 2024	SELL	$151.41 - $196.57 $2,573 - $3,341	-17 Reduced 0.23%	7,251 $1.39 Million
Q3 2023 Nov 03, 2023	SELL	$170.77 - $211.65 $25,444 - $31,535	-149 Reduced 2.01%	7,268 $1.29 Million
Q2 2023 Aug 09, 2023	SELL	$185.01 - $212.05 $108,785 - $124,685	-588 Reduced 7.35%	7,417 $1.41 Million
Q1 2023 May 09, 2023	SELL	$182.66 - $235.53 $4,749 - $6,123	-26 Reduced 0.32%	8,005 $1.6 Million
Q4 2022 Feb 13, 2023	SELL	$185.53 - $241.31 $39,332 - $51,157	-212 Reduced 2.57%	8,031 $1.91 Million
Q3 2022 Oct 27, 2022	BUY	$138.54 - $232.0 $27,292 - $45,704	197 Added 2.45%	8,243 $1.65 Million
Q2 2022 Aug 01, 2022	SELL	$120.42 - $169.29 $268,777 - $377,855	-2,232 Reduced 21.72%	8,046 $1.17 Million
Q1 2022 May 11, 2022	BUY	$127.18 - $173.91 $86,355 - $118,084	679 Added 7.07%	10,278 $1.68 Million
Q4 2021 Feb 11, 2022	BUY	$159.56 - $209.29 $160,836 - $210,964	1,008 Added 11.73%	9,599 $1.63 Million
Q3 2021 Nov 10, 2021	BUY	$169.75 - $207.73 $18,333 - $22,434	108 Added 1.27%	8,591 $1.62 Million
Q2 2021 Aug 05, 2021	BUY	$128.63 - $176.89 $30,742 - $42,276	239 Added 2.9%	8,483 $1.44 Million
Q1 2021 Apr 28, 2021	BUY	$126.83 - $175.69 $784,570 - $1.09 Million	6,186 Added 300.58%	8,244 $1.16 Million
Q4 2020 Feb 04, 2021	BUY	$122.97 - $147.0 $101,327 - $121,128	824 Added 66.77%	2,058 $268,000
Q3 2020 Nov 10, 2020	BUY	$121.19 - $165.49 $14,421 - $19,693	119 Added 10.67%	1,234 $179,000
Q2 2020 Aug 07, 2020	BUY	$104.21 - $156.44 $7,398 - $11,107	71 Added 6.8%	1,115 $165,000
Q1 2020 May 13, 2020	SELL	$93.12 - $133.99 $11,174 - $16,078	-120 Reduced 10.31%	1,044 $114,000
Q4 2019 Feb 04, 2020	BUY	$74.51 - $124.23 $3,576 - $5,963	48 Added 4.3%	1,164 $133,000
Q3 2019 Nov 08, 2019	BUY	$70.9 - $87.82 $34,599 - $42,856	488 Added 77.71%	1,116 $89,000
Q2 2019 Aug 13, 2019	BUY	$65.86 - $92.79 $17,057 - $24,032	259 Added 70.19%	628 $46,000
Q1 2019 May 08, 2019	BUY	$72.76 - $93.45 $10,695 - $13,737	147 Added 66.22%	369 $35,000
Q4 2018 Feb 13, 2019	SELL	$62.67 - $88.33 $4,762 - $6,713	-76 Reduced 25.5%	222 $16,000
Q3 2018 Nov 01, 2018	BUY	$87.52 - $122.67 $12,427 - $17,419	142 Added 91.03%	298 $26,000
Q2 2018 Aug 08, 2018	SELL	$88.31 - $107.8 $18,810 - $22,961	-213 Reduced 57.72%	156 $15,000
Q1 2018 May 08, 2018	BUY	$115.92 - $148.54 $14,837 - $19,013	128 Added 53.11%	369 $45,000
Q4 2017 Feb 02, 2018	SELL	$114.49 - $139.98 $25,416 - $31,075	-222 Reduced 47.95%	241 $30,000
Q3 2017 Nov 13, 2017	BUY	$72.53 - $118.27 $33,581 - $54,759	463	463 $55,000

Others Institutions Holding ALNY

# of Institutions

918

Shares Held

117M

Call Options Held

1.25M

Put Options Held

1.49M

View Full List

About ALNYLAM PHARMACEUTICALS, INC.

Ticker ALNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 123,028,000
Market Cap $55.3B
Description
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...

More about ALNY

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account